California’s stem cell agency has awarded $5.8 million to University of California San Diego (UCSD) researchers to develop a new variation of cancer immunotherapy.
The California Institute for Regenerative Medicine, or CIRM, approved the grant last week to adapt CAR T cell technology to fight cancer stem cells. These deadliest of cancer cells have stem cell-like properties that enable them to survive treatment and grow profusely. One surviving cell can recreate an entire tumor.
Already have an active account? Log in here.
Continue reading with one of these options:
Continue reading with one of these options:
Premium + Digital Edition
Ad-free access
P 80 per month
(billed annually at P 960)
- Unlimited ad-free access to website articles
- Limited offer: Subscribe today and get digital edition access for free (accessible with up to 3 devices)
TRY FREE FOR 14 DAYS
See details
See details
If you have an active account, log in
here
.